Introduction
Prostate cancer is a major cause of death in the developed world and is the most common cancer amongst men in the UK. Treatment options vary depending on grade and staging of patients. For patients with localised prostate cancer, active surveillance, radical prostatectomy or radiotherapy may be offered, but within this patient group a sub cohort will develop a subsequent recurrence and require further intervention [1] . For patients diagnosed with advanced disease, hormone therapy is normally the first choice of treatment with the majority of these patients eventually recurring with castrate resistant disease [2] . Therefore a major challenge facing today's urologists is predicting which patients are most likely to recur and what therapeutic strategy to employ when they do. In order to identify biomarkers and novel therapeutic options for these patients, further understanding of the pathways associated with promoting prostate cancer recurrence is required.
Deregulation of the signal transducers and activators of transcription factors (STAT)
along with the negative feedback regulators of the Janus-activated kinase (JAK), such as members of the SOCS family have been implicated in prostate cancer cell growth and survival [3, 4] . STAT members, a group of seven cytoplasmic proteins, act as transcription factors to elicit their effects via control of transcriptional expression of multiple genes. Aberrant activation of some STAT members, in particular STAT3 and STAT5, have been found in a large number of human tumours, acting as pro-survival signals for tumour cells via tight regulation of cell cycle progression, cellular transformation, and prevention of apoptosis [5, 6] .
Contrary to the function of other family members' in cancer development, STAT1 is believed to act as a tumour suppressor by playing an important role in growth progression and apoptosis. In early studies of the role of STAT1 in cancer, it was observed that STAT1 −/− mice formed significantly more carcinogen-induced S Hatziieremia et al.
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sarcomas than wild type mice [7, 8] . Recently, it was demonstrated in a subset of patients with ER± + /PR + breast cancer, that STAT1 expression is lost or significantly reduced in the neoplastic cells compared to normal breast epithelium [9] . Moreover, female mice lacking longitudinal expression of STAT1, spontaneously developed mammary gland cancers of the luminal subtype [9] . Numerous in vitro studies have also suggested that STAT1 may function as a tumour suppressor by regulating the expression of caspases such as caspase 1, 2, 3, and 7 [10, 11] upregulating p27 Kip1 expression [12] or interacting with p53 or BRCA1 [13, 14] . Paradoxically, STAT1
accumulation and hyper-activation has also been observed in multiple types of cancers, offering a survival advantage to these tumours. Elevated levels of STAT1 in squamous cell carcinoma cell lines have been linked to acquisition of resistance to radiation or chemotherapy treatment [15] . Furthermore, STAT1 along with clusterin protein expression was induced by docetaxel treatment in prostate cancer cells, DU145 and overexpressed in a docetaxel-resistant cell line (DU145-DR) [16] .
Therefore, STAT1 expression might be a double-edged sword that functions to either suppress or promote cancer development depending on the tissue or cellular context.
The current study was designed to investigate if STAT1 expression was associated with recurrence or patient survival in prostate cancer specimens at initial diagnosis.
Materials and Methods
Patient cohort. and response was defined as a fall in PSA levels of at least 50%. Tissue was obtained from patients by TRUS-guided biopsy or TURP, TMA was constructed (as described above) from the TURP specimens but full sections were used for the TRUS specimens. These patients were identified retrospectively and samples were retrieved from archived stored specimens. All tumours had patient identification removed, and the clinical information database was anonymised. Figure 1A ) and positive IHC staining was blocked by a peptide specific for the STAT1 antigen (Cell Signaling, UK; Figure 1B ). AR expression was already available for these cohorts from previous studies [17, 18] Scoring method. Protein expression levels were assessed blindly by two independent observers using a weighted histoscore method also known as the H- WST-1 assay as previously described by Tatarov et al. [20] . In brief, cell viability was measured by mitochondrial dehydrogenase induced cleavage of water soluble tetrazolium salt, via incubation with WST-1 for 2 hours at 37ºC with 5% CO 2 in air (Roche Applied Science, UK). Absorbance was then measured at 450nm.
Immunohistochemistry (IHC
Furthermore, cells were also plated at 3 x 10 4 cells/mL in octuplicates in E-Plate VIEW96 (Roche, UK) and their viability and proliferation was measured in real-time using the xCELLigence system (Roche,UK) as per manufacturer's instructions over Cell migration assay. Wound-healing assay was carried out to investigate the ability of PC3 cells to migrate into a denuded area after being transfected with siRNA for STAT1. Wounds were made using a fine pipette tip through the cell monolayer (three wounds per each well) of PC3 cells 48 hours post transfection with siRNA STAT1 in 6-well plates. The medium was then replaced with standard medium prior to assessing the wound closure using a Zeiss Axiovert S100 microscope at ×20 magnification. The assay was done over 20 hours with images taken from four fields per each well at 0, 4, 10, 16 and 20 hours. Closure of wound was assessed by measurement of the distance between the edges of the wound at each time point using ImageJ software.
Statistical Analysis. Statistical analysis was done using SPSS statistical package (version 19.0) and GraphPad Prism4. Survival analysis including time to disease recurrence and disease specific survival was conducted using the Kaplan-Meier method and curves were compared with the log-rank test. Multi variate analysis was performed using the Cox Regression model. In vitro experiments were analysed using one-way Anova and are expressed as mean ± s.e.m or % control mean (mean of treatment divided by mean of control x100). STAT1 expression was also assessed in the second patient cohort with advanced disease at initial diagnosis (table 1) . Briefly, at diagnosis the median age was 70,
Results
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Gleason grade was 8 and PSA level was 41•ng•ml Furthermore, the effect of STAT1 loss on migration of PC3 cells was measured using a wound healing assay. Wound closure was observed at a faster rate in cells silenced with siRNA STAT1 cells in comparison with control cells (Figure 6A and B).
More specifically 6h following generation of the wound, closure of the wound was more apparent in the PC3 cells silenced with siRNA STAT1 (wound closure 19.8% ± 7.6 %) in comparison to control cells (wound closure 7.5% ± 4.5 %, p<0.001; Figure   6A and 6B), this was also observed at 10 and 14 hours, with the difference in wound closure being most pronounced at 14 hours (wound closure of control 30.1% ± 1.8%, vs wound closure of siSTAT1: 76.9% ± 2.7%, p<0.001).
Discussion
Numerous transcription factors, growth factors and protein kinases have been associated with the progression of prostate cancer. However, the inability to completely control and thus eradicate the disease reveals that other unknown oncogenic signalling pathways may be involved in regulation of this disease. STAT1 signalling has previously been reported to be associated with cell viability in prostate cancer [21, 22] and we further investigated this in patient specimens. We observed that loss of STAT1 expression in patients with either localised or advanced prostate cancer at initial diagnosis was associated with shorter time to disease recurrence as well as shorter disease specific survival for patients with localised disease. Recently, EZH2 was demonstrated to up-regulate the STAT1 tumour suppressor action in DU145 and PC3 cells and therefore may be employed as a novel therapeutic agent in a subset of patients with low STAT1 levels [23] . In addition, Chan et al. reported that loss of STAT1 expression was linked with breast cancer development and progression, as STAT1-/-mice are highly susceptible to mammary tumour formation [9] . Conversely, in haematopoietic tumours such as leukaemia, high levels of STAT1 accelerated the expression of tumours independently of the IFN signaling pathway [24] , moreover in human soft tissue sarcoma specimens high expression of STAT1 was associated with reduced disease specific survival [25] . This contradictory data reveals that STAT1 may have different roles in different types of tumours either as a promoter or suppressor of the progression of the disease.
Interestingly, the localisation of STAT3 associated with disease recurrence was different in localised and advanced tumours. In localised tumours, membrane STAT3
was associated with shorter time to disease recurrence, suggesting that classical pathways may be important at this stage. However, in advanced prostate cancer, The key role of androgens and AR, not just in early development but also in the progression of prostate cancer is very well characterised. In order to evaluate a potential regulation of AR on STAT1 expression in clinical setting, we further stratified localised and advanced prostate cancer patient cohorts based on expression of AR.
When localised tumours were stratified into high and low AR-expression groups, associations between membrane STAT1 expression and time to disease recurrence was significant for both stratified groups (results not shown). But, in patients diagnosed with advanced disease, the association was lost in those that were AR positive but remained in those with no or low AR expression. This suggest that in advanced prostate cancer loss of STAT1 expression maybe a poor prognostic factor, and this may be specific to a subgroup of patients with low nuclear AR expression.
Furthermore, a study using the AR positive cell line LNCaP and the AR overexpressing cell line LNCaP-ARhi, demonstrated that STAT1 expression was not regulated in response to androgens or AR [26] . These facts combined suggest that STAT1 functions independently of the AR and it may be possible to use loss of STAT1 to identify patients with aggressive prostate cancer. Unfortunately, the number of patients with advanced prostate cancer in our cohort was relatively small, and this precluded any meaningful analysis of survival in this group; however, this data is interesting and further investigation in a larger cohort would be highly informative.
In addition, to our observations that STAT1 expression inversely correlates with ki67
proliferation index in the tissue specimens, we also in our cell line experiments and PC3 cells, which are both AR negative but not in LNCaP and 22RV1 cells which are both AR positive [23] . They hypothesize this due to Myc sensitivity in these cells, however an alternative explanation could be that STAT1 was not regulated in the LNCaP and 22RV1 due to AR status and not Myc status [23] , or conversely the observations made in the current study in the contrasting role of STAT1 loss in PC3
and LNCaP cells could be due to Myc sensitivity and not AR status.
In conclusion, the current study begins to build a body of evidence supporting the use of STAT1 loss as a prognostic marker for prostate cancer patients at diagnosis as well as in a subgroup of patients with low AR expression. for STAT1 is maintained at 72 hours and that silencing is specific to STAT1 as no effect is seen when lysates are probed with STAT3 antibody. 
